TheraStrand RX with I-Seed AgX100 I125 implants - Radionuclide source, therapeutic, brachytherapy, manual, permanent implant
Access comprehensive regulatory information for TheraStrand RX with I-Seed AgX100 I125 implants - Radionuclide source, therapeutic, brachytherapy, manual, permanent implant in the Australia medical device market through Pure Global AI's free TGA ARTG database. This AIMD is sponsored by RQSolutions Medical Devices Distribution Support, manufactured by Theragenics Corporation in United States of America. The device registration started on January 18, 2013.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.
Intended to treat localized, unresectable tumors with low to moderate radiosensitivity. Tumors may be recurrent, or residual following external beam or excision of primary tumor.